CVKD Cadrenal Therapeutics, Inc.

Nasdaq www.cadrenal.com


$ 12.23 $ 0.36 (3.03 %)    

Tuesday, 11-Nov-2025 13:48:08 EST
QQQ $ 622.04 $ 1.42 (0.23 %)
DIA $ 479.43 $ 5.36 (1.13 %)
SPY $ 683.22 $ 3.24 (0.48 %)
TLT $ 89.92 $ -0.03 (-0.03 %)
GLD $ 379.43 $ -0.58 (-0.15 %)
$ 11.76
$ 11.87
$ 12.14 x 100
$ 12.44 x 100
$ 12.00 - $ 12.23
$ 8.74 - $ 22.90
13,176
na
24.04M
$ 4.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-08-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cadrenal-therapeutics-q3-eps-131-beats-153-estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of...

 cadrenal-acquires-assets-of-exithera-pharma-in-15m-milestone-linked-deal-adds-royalty-pathway-for-future-global-sales

Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation setti...

 cadrenal-therapeutics-q2-eps-187-misses-160-estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate ...

 cadrenal-therapeutics-highlights-tecarfarin-as-safer-anticoagulant-alternative-for-high-risk-lvad-patients

LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascul...

 hc-wainwright--co-reiterates-buy-on-cadrenal-therapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $32...

 cadrenal-therapeutics-announces-manufacturing-and-supply-chain-milestones-for-tecarfarin-oral-vka-anticoagulant-designed-to-address-unmet-needs-in-anticoagulation-therapy

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular...

 cadrenal-therapeutics-q1-eps-209-misses-125-estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(2.09) per share which missed the analyst consensus estimate ...

 cadrenal-therapeutics-fy-2024-gaap-eps-873-misses-759-estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(8.73) per share which missed the analyst consensus estimate ...

Core News & Articles

Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemoc...

 hc-wainwright--co-maintains-buy-on-cadrenal-therapeutics-adjusts-price-target-to-32-1-15-reverse-stock-split

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy, adjusts target to $3...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION